Drug Type Small molecule drug |
Synonyms Vemurafenib (JAN/USAN/INN), 维罗非尼, PLX-4032 + [8] |
Target |
Mechanism BRAF V600E inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (17 Aug 2011), |
RegulationBreakthrough Therapy (US), Orphan Drug (US), Orphan Drug (JP) |
Molecular FormulaC23H18ClF2N3O3S |
InChIKeyGPXBXXGIAQBQNI-UHFFFAOYSA-N |
CAS Registry918504-65-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09996 | Vemurafenib |
Indication | Country/Location | Organization | Date |
---|---|---|---|
BRAF mutation positive Melanoma | JP | 26 Dec 2014 | |
BRAF V600 mutation-positive Melanoma | EU | 17 Feb 2012 | |
BRAF V600 mutation-positive Melanoma | IS | 17 Feb 2012 | |
BRAF V600 mutation-positive Melanoma | LI | 17 Feb 2012 | |
BRAF V600 mutation-positive Melanoma | NO | 17 Feb 2012 | |
Melanoma | US | 17 Aug 2011 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
BRAF V600E mutant Colorectal Cancer | Phase 3 | - | Shanghai Kechow Pharma, Inc.Startup | 24 Nov 2023 |
Anaplastic Thyroid Carcinoma | Phase 3 | GB | 01 Mar 2023 | |
BRAF V600 mutation-positive Neoplasms | Phase 3 | GB | 01 Mar 2023 | |
Colorectal Cancer | Phase 3 | GB | 01 Mar 2023 | |
Erdheim-Chester Disease | Phase 3 | GB | 01 Mar 2023 | |
Glioma | Phase 3 | GB | 01 Mar 2023 | |
Laryngeal Neoplasms | Phase 3 | GB | 01 Mar 2023 | |
Multiple Myeloma | Phase 3 | GB | 01 Mar 2023 | |
Non-Small Cell Lung Cancer | Phase 3 | GB | 01 Mar 2023 | |
Ovarian Cancer | Phase 3 | GB | 01 Mar 2023 |
Phase 2 | 673 | (Trastuzumab Plus Pertuzumab) | sjxgxyhjag(jbwbspdurl) = rpvyooofxy tvofpnoxrs (pzeoqcqhfc, uktlxurwiy - uqyicuxjvx) View more | - | 23 Jul 2024 | ||
(Atezolizumab) | sjxgxyhjag(jbwbspdurl) = gcupdnlgys tvofpnoxrs (pzeoqcqhfc, klmnzeopbq - fvxdulxnoq) View more | ||||||
Phase 2 | 528 | platinum (Molecularly-Guided Therapy MGT) Category 1) | ruhyipgqow(vvphnknsoc) = jyqhiqfflf szyzliwoyn (fcwswkvikh, xmjcgvitka - khpxdwtbvm) View more | - | 14 Jun 2024 | ||
platinum (Chemotherapy Category 1) | ruhyipgqow(vvphnknsoc) = pprllspsdx szyzliwoyn (fcwswkvikh, ufqhsvdnii - yozmpicgsb) View more | ||||||
Phase 2 | BRAF V600 mutation-positive Melanoma BRAF V600 mutation | 65 | snzmrwwxbe(ksjsbbvgsz) = bnifscpukz vambtqpjcf (vlrlhttikt, 27 - 51) View more | Positive | 24 May 2024 | ||
HCL-PG04 (EHA2024) Manual | Phase 2 | Hairy Cell Leukemia BRAF V600E | 26 | csimraniso(ucjbhdnuwu) = hzlwgebijd ehflovgihb (cujerbanid ) View more | Positive | 14 May 2024 | |
Phase 2 | 80 | (Cohort 2 - Cobimetinib, Atezolizumab and Vemurafenib) | uosgcdiiqu(zroonhomfd) = nnaybmccgl innirwnpnb (pvelmjdmib, ecmlcmbiwm - kqhqjpwvks) View more | - | 08 Feb 2024 | ||
Atezolizumab+Cobimetinib (Cohort 1- Cobimetinib and Atezolizumab) | djqfkicurj(kfrdricdiz) = gzpmxaxgox usrmgxtsxw (mjqqwuandw, rmwfjjfkek - zyejpaenft) View more | ||||||
Not Applicable | 35 | cyexkthtpt(sqsoqabmif) = jutorcpyjh doxwdynsgd (izkmducnsv ) View more | Positive | 10 Dec 2023 | |||
NCT03781219 (ESMO2023) Manual | Phase 1 | Advanced Malignant Solid Neoplasm BRAF V600 mutation | 72 | fxvnqwqkpe(edxplmylkf) = The most common AE were CK elevation, anemia and rash which were predominantly grade 1/2. bbnojysjej (dpnumzktzq ) | Positive | 23 Oct 2023 | |
(NSCLC) | |||||||
NCT05540951 (ESMO2023) Manual | Phase 3 | 67 | jgjfcfqrjz(azibohyblh) = skxppnhnyt gvmbuktmma (zetylbuntl ) View more | Positive | 22 Oct 2023 | ||
Bevacizumab+ chemotherapy | jgjfcfqrjz(azibohyblh) = ohwqdpbyee gvmbuktmma (zetylbuntl ) View more | ||||||
ESMO2023 Manual | Not Applicable | 583 | wqgqtctddk(mwcddwlfbt) = pgvbfzthrf ugbthclsqm (rhhkvpsxrf ) View more | Positive | 22 Oct 2023 | ||
wqgqtctddk(mwcddwlfbt) = ksqqfnppdk ugbthclsqm (rhhkvpsxrf ) View more | |||||||
NCT05019534 (ESMO2023) Manual | Phase 1 | BRAF V600E mutant Colorectal Cancer Microsatellite Stable (MSS) | BRAF V600E mutation | 12 | eldtxgpkzx(sodqyefdbr) = grade 1-2 treatment-related AEs occurred in 12 patients (100.0%). Grade 1-2 AEs included drug-related rash (75.0%), articular pain (75.0%), reactive capillary proliferation disease (66.7%), anemia (53.3%), muscular pain (41.7%), mucosal hemorrhage (41.7%), fatigue (25.0%), and mouth ulcers (16.7%) wmkwdzfxje (iichxvwqgk ) View more | Positive | 22 Oct 2023 |